Search results
Results From The WOW.Com Content Network
Nifedipine, sold under the brand name Procardia among others, is a calcium channel blocker medication used to manage angina, high blood pressure, Raynaud's phenomenon, and premature labor. [2] It is one of the treatments of choice for Prinzmetal angina. [2] It may be used to treat severe high blood pressure in pregnancy. [2]
Raynaud’s occurs in 2% to 5% of the population, more commonly in women, and takes two forms. Primary Raynaud’s is by far the most common and is typically diagnosed in teenage girls and women ...
CREST syndrome, also known as the limited cutaneous form of systemic sclerosis (lcSSc), is a multisystem connective tissue disorder.The acronym "CREST" refers to the five main features: calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.
Patients with secondary Raynaud's can also have symptoms related to their underlying diseases. Raynaud's phenomenon is the initial symptom that presents for 70% of patients with scleroderma, a skin and joint disease. [citation needed] When Raynaud's phenomenon is limited to one hand or one foot, it is referred to as unilateral Raynaud's.
It is recommended to name the SVG file “Consensus Diagnostic Criteria Raynaud's Phenomenon.svg”—then the template Vector version available (or Vva) does not need the new image name parameter. Summary
Raynaud’s phenomenon is usually more annoying than serious — although severe (and rare) cases can lead to tissue death in the hands or feet, which could require amputation.
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
Sclerodactyly is one component of the limited cutaneous form of systemic sclerosis (lcSSc), also known as CREST syndrome (CREST is an acronym that stands for calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.) [4] Sclerodactyly is also one component of Huriez Syndrome, along with palmoplantar ...